ASSEMBLY BIOSCIENCES, INC.
Business
Assembly Biosciences is a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases. The company's pipeline includes clinical-stage investigational therapies for recurrent genital herpes, hepatitis delta virus, hepatitis B virus, and transplant-associated herpesviruses. Assembly operates under a collaboration with Gilead Sciences, which has licensed certain programs and retains options to license additional candidates. The company distributes products through clinical trials and future regulatory approval pathways in the United States, Europe and other geographies.
Summary from 10-K filed 2026-03-19
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Collaboration revenue from a related party | 72 | 29 | — | — | — | |
| Research and development | 65 | 56 | 49 | 70 | 69 | |
| General and administrative | 20 | 18 | 23 | 24 | 29 | |
| Total operating expenses | 84 | 74 | 72 | 94 | 139 | |
| Loss from operations | −12 | −45 | −65 | −94 | −133 | |
| Interest and other income, net | 6 | 6 | 3 | 1 | 302,000 | |
| Total other income | 6 | 6 | 3 | 1 | 302,000 | |
| Loss before income taxes | −6 | −40 | −61 | −93 | −132 | |
| Income tax expense | 0 | 330,000 | 33,000 | 0 | 3 | |
| Net loss | −6 | −40 | −61 | −93 | −130 | |
| Unrealized gain (loss) on marketable securities | 170,000 | −130,000 | 722,000 | −384,000 | −149,000 | |
| Comprehensive loss | −6 | −40 | −61 | −93 | −130 | |
| Net loss per share - basic | −0.55 | −6.69 | −13.38 | −23.08 | −3 | |
| Net loss per share - diluted | −0.55 | −6.69 | −13.38 | −23.08 | −3 | |
| Weighted average common shares outstanding, basic | 11 | 6 | 5 | 4 | 43 | |
| Weighted average common shares outstanding, diluted | 11 | 6 | 5 | 4 | 43 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 58 | 38 | 20 | 52 | 46 | |
| Marketable securities | 190 | 74 | 110 | 39 | 101 | |
| Accounts receivable from collaboration with a related party | 974,000 | 0 | 43,000 | 944,000 | 336,000 | |
| Prepaid expenses and other current assets | 5 | 3 | 3 | 4 | 7 | |
| Total current assets | 255 | 116 | 134 | 97 | 154 | |
| Property and equipment, net | 221,000 | 284,000 | 385,000 | 743,000 | 1 | |
| Operating lease right-of-use (ROU) assets | 3 | 3 | 2 | 3 | 6 | |
| Other assets | 312,000 | 312,000 | 312,000 | 889,000 | 2 | |
| Total assets | 258 | 119 | 137 | 102 | 191 | |
| Accounts payable | 1 | 585,000 | 461,000 | 2 | 3 | |
| Accrued research and development expenses | 2 | 2 | 885,000 | 3 | 3 | |
| Other accrued expenses | 8 | 7 | 6 | 7 | 7 | |
| Deferred revenue from a related party - short-term | 37 | 38 | 31 | — | — | |
| Operating lease liabilities - short-term | 569,000 | 461,000 | 1 | 3 | 3 | |
| Total current liabilities | 49 | 48 | 39 | 16 | 16 | |
| Deferred revenue from a related party - long-term | 0 | 35 | 55 | 3 | 3 | |
| Operating lease liabilities - long-term | 2 | 3 | 1 | 101,000 | 3 | |
| Total liabilities | 51 | 86 | 96 | 19 | 22 | |
| Commitments and contingencies | — | — | — | — | — | |
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding | — | — | — | — | — | |
| Common stock, $0.001 par value; 150,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 15,855,329 and 7,457,240 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 16,000 | 7,000 | 5,000 | 4,000 | 48,000 | |
| Additional paid-in capital | 1,039 | 859 | 827 | 808 | 801 | |
| Accumulated other comprehensive loss | −41,000 | −211,000 | −81,000 | −803,000 | −419,000 | |
| Accumulated deficit | −832 | −826 | −786 | −725 | −631 | |
| Total stockholders' equity | 207 | 33 | 41 | 83 | 169 | |
| Total liabilities and stockholders' equity | 258 | 119 | 137 | 102 | 191 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −6 | −40 | −61 | −93 | −130 | |
| Depreciation and amortization | 129,000 | 129,000 | 450,000 | 498,000 | 466,000 | |
| Stock-based compensation | 5 | 3 | 5 | 7 | 5 | |
| Net accretion of investments in marketable debt securities | −2 | −4 | −2 | 155,000 | — | |
| Non-cash rent expense | 851,000 | 1 | 4 | 4 | 4 | |
| Realized gain on investments in marketable debt securities | −3,000 | 0 | — | — | — | |
| Accounts receivable from collaboration | −974,000 | 43,000 | 901,000 | −608,000 | 894,000 | |
| Prepaid expenses and other current assets | −2 | 73,000 | 916,000 | 1 | 1 | |
| Accounts payable | 586,000 | 124,000 | −2 | −166,000 | −2 | |
| Accrued research and development expenses | 114,000 | 1 | −2 | −278,000 | −1 | |
| Other accrued expenses | 887,000 | 1 | −2 | 458,000 | −5 | |
| Deferred revenue from a related party | −36 | −13 | 84 | 0 | −6 | |
| Operating lease liabilities | −751,000 | −1 | −4 | −4 | −4 | |
| Net cash used in operating activities | −41 | −51 | 23 | −84 | −93 | |
| Proceeds from maturities of marketable securities | 116 | 131 | 65 | 88 | 175 | |
| Purchases of marketable securities | −230 | −91 | −134 | −28 | −160 | |
| Purchases of property and equipment | −66,000 | −28,000 | −255,000 | −102,000 | −3 | |
| Net cash (used in) provided by investing activities | −113 | 40 | −69 | 91 | 27 | |
| Proceeds from the issuance of common stock, pre-funded warrants and warrants in an underwritten offering, net of issuance costs | 124 | 0 | — | — | — | |
| Proceeds from the issuance of common stock and warrants in private placements to a related party, net of issuance costs | 43 | 18 | 9 | — | — | |
| Proceeds from the exercise of warrants | 6 | 0 | — | — | — | |
| Proceeds from the issuance of common stock under ATM equity offering program, net of issuance costs | 2 | 2 | 5 | 325,000 | 53 | |
| Proceeds from the issuance of common stock under ESPP | 725,000 | 150,000 | 129,000 | 289,000 | 258,000 | |
| Proceeds from the exercise of stock options | 125,000 | 5,000 | 0 | — | 0 | |
| Proceeds from the issuance of common stock and warrants in a registered direct offering, net of issuance costs | 0 | 10 | 0 | — | — | |
| Net cash provided by financing activities | 175 | 29 | 14 | 614,000 | 53 | |
| Net increase in cash and cash equivalents | 20 | 19 | −33 | 7 | −14 | |
| Operating lease liabilities arising from obtaining ROU assets | 0 | 2 | 2 | 171,000 | 126,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is ASSEMBLY BIOSCIENCES, INC.'s CIK number?
ASSEMBLY BIOSCIENCES, INC.'s SEC CIK number is 0001426800 (1426800). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find ASSEMBLY BIOSCIENCES, INC.'s SEC filings?
All of ASSEMBLY BIOSCIENCES, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did ASSEMBLY BIOSCIENCES, INC. last report earnings?
ASSEMBLY BIOSCIENCES, INC. (ASMB) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-211922). This is ASSEMBLY BIOSCIENCES, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is ASSEMBLY BIOSCIENCES, INC.'s most recent earnings 8-K?
ASSEMBLY BIOSCIENCES, INC.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001193125-26-211922. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View ASSEMBLY BIOSCIENCES, INC.'s latest earnings 8-K →
Look up any company's CIK number →